Endocrine Abstracts

Aims/objectives: The aims of the audit were to assess if Sodium Glucose Cotransporter-2 inhibitors (SGLT2) were initiated in accordance with National institute of clinical excellence guidelines and appropriate effectiveness and reviews were performed in accordance with these guidelines.

Methods: A retrospective audit of 31 patients with Type 2 diabetes prescribed Sodium Glucose Cotransporter-2 inhibitors (SGLT2) between March 2014 and January 2017 at Nottingham University Hospitals was performed across both hospital sites in February 2017. The data was collected from the hospital software systems NOTIS and DIAMOND.

Results: The collected data showed patient’s age range was between 26 and 83 years and duration of diabetes ranging from 4 years to 32 years. The audit demonstrated a significant reduction in HbA1C by 9.76 mmol per mol but no significant reduction in Blood Pressure or Body Mass Index after 6 months of therapy. The National Institute of clinical excellence targets for initiation (97%) and annual review (100%) of Sodium Glucose Cotransporter-2 Inhibitors (SGLT2) were achieved but the standards for documentation of the benefits and risks and continuation of therapy were not achieved.

Conclusions: The audit demonstrated that standards for initiation and annual reviews of the therapy were met but standards for documentation and continuation of therapy need improvement. We conclude that the significant optimisation of glycaemic control and osmotic symptoms despite a minimal reduction in Blood Pressure and Body Mass Index is promising enough to not preclude the use Sodium Glucose Cotransporter-2 inhibitors on further clinical reviews.